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Abstract
Background: Drug resistant HIV-1 variants were emergent more and more in AIDS individuals
with highly active antiretroviral therapy (HAART) treatment. Understanding the replication and
drug resistant mutation of HIV-1 variants isolated from HAART treatment individuals of China
could help to design appropriate therapeutic strategies for these individuals.
Methods: Use GHOST cell lines to analysis the coreceptor usage of HIV-1 variants. Coculture
with PBMCs to analysis the replication capacity. Use RT-PCR to analysis the drug resistant
mutation of pol gene.
Results: 13 HIV-1 variants experienced HAART were included in this study. 5 HIV-1 variants used
CCR5 coreceptor (R5), while 8 use both CCR5 and CXCR4 coreceptor (R5X4). The replication
capacity of R5X4 variants was no difference with R5 variants in vitro without antiretroviral drugs.
Compare the drug resistant mutation between first HIV-1 variants and fourth variants; there were
37 drug resistant mutations in first variants and 32 drug resistant mutations in fourth variants. Only
7 drug resistance mutations were lost after coculture for 4 weeks, and 2 drug resistance mutations
were emerged.
Conclusion: These data suggested that the drug resistant level could not reduce in vitro in
absence of antiretroviral drugs in few weeks. And maybe helpful for these HAART experienced
individuals when change antiretroviral drugs.
Background
HAART therapies have dramatically reduced the mortality
rate from human immunodeficiency virus (HIV) in the
developed world[1]. Unfortunately, current therapies are
not curative, and many treated patients develop resistance
to one or more drugs, which is costly and may lead to
complete treatment failure and death. The drug resistant
HIV-1 variants emergent in HAART treatment individuals
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are the major obstacle to antiviral therapy and these drug-
resistant variants may transmit in newly infected individ-
uals[2,3].
By the end of 2007, it was estimated that there were
700,000 people living with HIV/AIDS in China. Most of
these patients are being treated by antiretroviral treatment
regimens. The provision of treatment was expanded to
1,190 counties in 31 provinces (autonomous regions and
municipalities) at the end of 2007. http://www.china
ids.org.cn/n435777/n443716/appendix/
Joint_Assessment_EN.pdf. it have been reported that the
drug resistant variants were emergent with the time of
treatment, cause of treatment failure [4-6]. Therefore,
design a second-line HAART therapy for HAART failure
individuals is urgently needed. Unfortunately, there were
also few antiretroviral drugs for consideration.
Better understand the biological phenotype of HIV-1 var-
iants from these HAART experienced individuals could
help to design appropriate therapeutic strategies for these
individuals. Here, we detected the viral replication level
and drug resistant mutation of 13 variants isolated from
AIDS patients experienced HAART of Henan and Anhui
province in China[6].
Methods
HIV-1 variants and cells
HIV-1 variants were isolated from HIV-1 infected individ-
uals of Henan and Anhui province, treated time range 6-
18 months. those isolate had been identified as drug-
resistance using both genotypic assay and phenotypic
assay [6]. SF33, dual tropic, use CCR5 and CXCR4 core-
ceptor for entry cells, as positive control.
GHOST cells were derived from the human osteosarcoma
cell line, HOS, stably express CD4 and the chemokine
receptor CXCR4 or CCR5. The GHOST parental cell
expressing human CD4 was grown in Dulbecco's modi-
fied Eagle's medium supplemented with 10% fetal bovine
serum, 1% glutamine, 2% penicillin plus streptomycin,
Geneticin (500 μg/ml, Gibco, Paisley, Scotland), hygro-
mycin (100 μg/ml, Gibco). GHOST cells expressing one of
the coreceptors CCR5 and CXCR4 were cultivated in
medium additionally supplemented with puromycin (1
μg/ml; Sigma, Deisenhofen, Germany)[7,8].
Human peripheral blood mononuclear cells (PBMC)
were obtained by Ficoll density centrifugation. were
grown in an RPMI 1640(Gibco)-based culture medium
supplemented with 10% fetal calf serum (HyClone,
Logan, Utah), 2 mM L-glutamine(Gibco), penicillin (100
U/ml), streptomycin (100 mg/ml), and 20 U/ml of
recombinant interleukin-2.
Coreceptor usage
Coreceptor usage was determined with the GHOST(3)-
CXCR4 and GHOST(3)-CCR5 cell lines[7,8]. Briefly,
GHOST cells were seeded in 24-well plates (Corning
Incorporated) at 6*104cells/well. On the following day,
the medium was removed, infected with virus stocks in
the presence of 8 μg/ml DEAE to enhance infection effi-
ciency. Cells were harvested at 48 h after infection, then
using flow cytometer (Elite ESP, Beckman Coulter) to ana-
lyze the GFP expression. A total of 10,000 to 15,000
events were scored. We expected an approx 10-fold shift in
mean GFP fluorescence of infected cells over non-
infected[8]. A positive control (SF33) and cell control
were included in each experiment to assess inter-assay var-
iation and cell auto fluorescence.
Assessment of replication capacity
At least 2 HIV-1 negative PBMC and HIV-1 variant were
coculture[9]. Briefly, 5*106 PBMC cells from normal
seronegative donors were stimulated with 1 ug of PHA per
ml for 2-3 days, were infected overnight with 2 ng of p24
antigen equivalent of each viral isolate, washed, and
resuspended in complete medium supplemented with
recombinant interleukin-2. Aliquots of virus supernatant
were collected every 2 to 3 days and monitored for p24
antigen production over 13 days with a commercially
available ELISA (Vironostika HIV-1 Microelisa system,
bioMérieux, France)
Nucleic acid extraction, amplification and sequencing
RNA was extracted from the plasmas and HIV variants
using a QIAamp® Viral RNA Mini Kit (Qiagen Inc., Chats-
worth, CA).
For synthesis of cDNA, 5 μl extracted RNA, 10 pmol
downstream PCR primer (RT21: CTGTATTTCTGCTAT-
TAAGTCTTTTGATGGG; HXB2 3509-3539), M-MuLV
reverse transcriptase (NEW ENGLAND BioLabs) and
Ribonuclease Inhibitor (TaKaRa Biotechnology) were run
for 60 min at 45°C in a thermal cycler (GeneAmp® PCR
system 9700, Applied Biosystems, Foster City, CA). A
nested PCR strategy was employed to amplify the 1,100-
bp RT fragment. cDNA (10 μl) was used as a template and
the outer primer set (MAW 26: TTggAAATgTggAAAggAAg-
gAC; HXB2 2027-2050 and RT21) was used in the first
round of PCR. The amplification was done at 94°C for 5
min, followed by 35 cycles at 94°C for 20 sec, 55°C for 20
sec and 72°C for 2 min, and finally an extension of 7 min
at 72°C. The first-round PCR product (5 μl) and the inner
primer set (PRO-1: CAgAgCCAACAgCCCCACCA; HXB2
2147-2166 and RT20: CTgCCAgTTCTAg CTCTgCTTC;
HXB2 3441-3462) were used in the second round of PCR.
The amplification was performed at 94°C for 5 min, fol-
lowed by 35 cycles at 94°C for 20 sec, 55°C for 20 sec,Virology Journal 2009, 6:201 http://www.virologyj.com/content/6/1/201
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and 72°C for 1 min, and finally an extension of 7 min at
72°C.
The nested PCR product was purified using a QIAquick
Gel Extraction Kit (Qiagen Inc., Chatsworth, CA). DNA
was sequenced with the ABI 3100 DNA Sequencer
(Applied Biosystems Inc). The primers used for DNA
sequencing were PRO-1, RT-20, RT-A (gTTgACTCAgATT-
ggTTgCAC; HXB2 2519-2539), and RT-B (CCTAg-
TATAAACAATgAgACAC; HXB2 2946-2967).
The pol gene of HIV-1 subtype B' were sequenced and
compared to the consensus B reference sequence, using
the HIVdb software (Stanford HIV Drug Resistance Data-
base, http://hivdb.stanford.edu) to detect drug resistance
mutations.
Statistical Analysis
Difference between R5 drug resistance variants and R5X4
drug resistance variants were compared using T analysis.
Two-tailed P values less than 0.05 was considered statisti-
cally significant. All statistical analyses were completed by
the GraphPad5.0 software.
Results
Characterization of HIV-1 variants
13 HIV-1 variants were isolated from AIDS patients (4
male and 9 female; average 40.3 years old) were recruited
for this study. 4 patients received AZT + ddI + NVP, and 9
were treated with d4T + ddI+ NVP for 6 months or longer.
The average viral load was 8.08 × 105 copies/ml (range
from 5.0 × 102 ~ 4.0 × 106 copies/ml), and the average
CD4 count was 151 cells/ul (range from 63 ~ 348 cells/
ul).
Using GHOST cell line to determined the coreceptor
usage, We found 5/13 viral variants were CCR5-tropic(R5)
as determined by parallel infection of GHOST(3)-CXCR4
and GHOST(3)-CCR5 cells, 8/13 viral variants were CCR5
and CXCR4-tropic(R5X4). Among 13 drug-resistant vari-
ants, the CD4 T counts of R5X4 variants were 97.9 (range
from 63 to 186), while that of R5 variants were 236.2
(range from 144 to 348/μl; P = 0.04). The R5X4 variants
mainly appeared in CD4 counts <200/ul. Viral load of
R5X4 variants were 4.91 ± 1.58, while that of R5 variants
were 5.67 ± 0.33. There was no difference in viral load
between R5X4 variants and R5 variants (P = 0.32). The
average time under HAART were no difference between
R5X4 variants and R5 variants, 13.1 and 15.6 months,
respectively (P = 0.4).
Replication of HIV-1 variants in stimulated PBMCs 
without antiretroviral drugs
HIV-1 variants growth kinetics analyzed by determined
the level of p24 antigen at 1, 3, 7, 10, 12 days after HIV-1
variants infection. All HIV-1 variants were able to yield
productive infections in PBMCs assay. But all HIV-1 vari-
ants produce less 10000 pg/ml at 12 day. Compare the
p24 values at 1, 3, 7, 10, 12 day, the growth kinetics of R5-
tropic HIV-1 variants was similar with R5X4-tropic HIV-1
variants (fig 1A, p > 0.05).
Although the mean p24 antigen level of R5-tropic variants
was lower than that of R5X4 variants. In some case, R5
variants replicated more efficiently than R5X4 viruses, for
example, V13 variant was more efficiently than V1, V3, V4
and V5 variant (fig 1B).
Drug-resistant mutation between first and fourth HIV-1 
variants
HIV-1 variants placed in a humidified chamber at 37°C
with 5% CO2 air and maintained for 4 weeks without
antiretroviral drugs. Compare the drug resistant muta-
tions of pol gene between first and fourth variants. There
Replication kinetics of HIV strains isolated from patient's  PBMCs Figure 1
Replication kinetics of HIV strains isolated from 
patient's PBMCs. A: compare the mean p24 antigen level 
of R5 variants and R5X4 variants; B: p24 level of one R5 vari-
ants and 4 R5X4 variants. Virus replication was monitored by 
measuring p24 antigen level in supernatant of duplicate cul-
tures of each virus.
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was no primary drug mutation of protease both in first
and fourth HIV-1 variants. In first HIV-1 variants, 37 pri-
mary drug mutations including 16 NRTI mutations and
21 NNRTI mutations were detected. For NRTI, there were
4 HIV-1 variants were mutated at 215 site, including
T215Y and T215F mutation. The most frequency muta-
tions of NNRTI were at 181 and 103 site (fig 2). 32 pri-
mary drug mutations including 13 NRTI mutations and
19 NNRTI mutations were detected in fourth HIV-1 vari-
ants. The most frequency mutation of NRTI was at 215
site. There were 7 mutations at 181 site, and 6 mutations
at 103 site, for NNRTI.
Compare the drug resistant mutation at 215 site between
first and fourth variants, there were no difference. The
mutation at 181 site was lost in one HIV-1 variant, and
emergent in another HIV-1 variant. K103N mutation was
lost in one variant after coculture.
The NRTI drug resistant mutations lost in 3 strains after
coculture, including T69APST, M41LM, and A62V. One
drug resistant mutation (L74V) changed to V75T. The
NNRTI drug resistant mutations lost in 3 strains, includ-
ing K103N, K101*EKQ, Y181C and V108FILV. 2 drug
resistant mutations (V108I and Y181C) emergent after
coculture. One drug resistant mutation (G190EV)
changed to G190A (table 1).
Discussion
HIV-1 entry into cells requires interactions with certain
coreceptors in addition to CD4. Several studies have
shown that the CCR5 acts as the major coreceptor for pri-
mary non-T-cell-line-adapted viruses[10,11]. Virus vari-
ants use CCR5 co-receptor for entry was R5 phenotype,
also referred to as non-syncytium-inducing (NSI) viruses.
X4 phenotype referred to SI phenotype and T-cell-line-
adapted HIV-1 strains instead use the CXCR4 as corecep-
tor[12,13]. The coreceptor antagonist such as Maraviroc,
is a new class of drugs approved to apply in combination
with other antiretroviral drugs for the treatment of adults
with CCR5-tropic HIV-1, who have been treated with
other HIV medications and who have evidence of elevated
levels of HIV in their blood (viral load)[14]. We deter-
mined the coreceptor usage of 13 drug resistant variants
based the GHOST cell line. Interesting, there were
8(61.5%) drug resistant variants were use CCR5 and
CXCR4 coreceptor for entry cells (R5X4). In our previous
work, we found that 40%-50% patients with HIV-1 sub-
type B' infection native to HAART treatment, would
switch from R5 phenotype to R5X4 phenotype with dis-
ease progression[15]. Therefore, the R5X4 phenotype
would more general in drug resistant variants from
HAART treatment individuals, suggested that the inhibi-
tor of CCR5 may be less useful in these individuals.
CD4 T cell counts of all R5X4 phenotype were less than
200 cells/ul (mean is 97.9 ± 50.2), while that of R5 phe-
notype range from 144 to 348 cells/ul (mean is 236.2 ±
91.6, P = 0.04). There was no difference between R5X4
phenotype viral load (4.91 ± 1.58) and R5 phenotype
viral load (5.67 ± 0.33, P = 0.32). It have been proved that
the emergence of SI viruses is associated with an acceler-
ated decrease in CD4 T cell count, rapid disease progres-
sion and the establishment of AIDS[16,17]. In HAART
treatment individuals with HIV-1 subtype B' infected, the
emergence of variants use CXCR4 coreceptor may be
imply the severe disease progression.
It is believed that replication capacity is an important
determinant of HIV-1 pathogenicity and transmissibility.
We analysis the replication properties of 13 drug-resistant
variants using PBMC assay. The data show all drug resist-
ant variants were able to yield productive infections in
PBMCs. Suggested that drug-resistant HIV-1 isolates can
Prevalence of first and forth HIV-1 variants with mutations for genotypic resistance to NRTI and NNRTI Figure 2
Prevalence of first and forth HIV-1 variants with mutations for genotypic resistance to NRTI and NNRTI.
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bear adaptive mutations that allow for wild-type-level rep-
licative function, thereby overcoming the potential
defects associated with the genetic changes necessary for
drug resistance. Interestingly, the p24 antigen level of
drug-resistant variants were lower than 10 ng at 7 day after
infection, while the drug sensitivity variants usually reach
10 ng at 7 day after infection in our lab previous work
(data unpublished). This result was coincides with several
other reports [18-20], that the drug resistant HIV variants
showed a decreased replication capacity than wild-type
strains in the absence of antiretroviral therapy.
The drug resistance mutation in protease (PR) and reverse
transcriptase (RT) genes responsible for escape drug inhi-
bition and some may responsible for moderate viral fit-
ness[21]. We compared the drug resistance mutation
between first variants and fourth variants in the absence of
drugs. Only 7 out of 37 mutations were lost and emerged
2 mutations compare the first and fourth variants. Inter-
estingly, the mainly primary mutations such as T215F,
Y181C were stable in vitro environment in the absence of
antiretroviral drugs. These data suggested that the drug
resistant variants were stable in vitro culture in the
absence of drugs. Simon[18] also show that in vitro cul-
ture did not reduce the level of drug resistance. Therefore,
when design the second-line HAART therapy for HAART
failure individuals, it should substitute the drugs belong
to new class such as fusion inhibitors or integrase inhibi-
tors, instead of the same class.
Due to the decreased replication capacity of drug resistant
variants, there is a hypothesis that when antiretroviral
treatment is interrupted or terminated, drug-resistant var-
iants in the quasispecies are rapidly replaced by the most
fit wild-type virus. And it has been noted that after cessa-
tion of treatment following failure, resistant virus is often
replaced by wild-type virus[22]. These have clinical rele-
vance in terms of selecting optimal therapies and reducing
the rate of progression, as well as on the modeling of the
epidemiology of transmission of resistant HIV-1strains.
However, the drug resistant mutations in vitro in absence
of drugs were persistent and only 7 mutations were lost
after passage suggested that the drug resistant variants
were predominant in culture. On the other hand, rever-
sion to the wild type amino acid appears to occur infre-
quently[23]. Our data also show that the drug resistant
mutation to wild type can occur at 41, 62, 69, 101, 103,
108, 181, ect. Therefore, the cessation of treatment should
be carefully and discussed more[24]. Furthermore, even
less fit, drug resistant variants will probe the sequence
space and fitness landscape under drug pressure and even-
tually evolve as a more fit isolate, i.e. one that is stable in
the quasispecies upon removal of drug pressure and that
can be transmitted to new human recipients[25]. Here, we
use HIV-1 clinical variants instead of recombinant infec-
tious clones to measure viral biological phenotype, and
should be noted that our drug resistant variants were HIV-
1 quasispecies, since the quaisispace variants responsible
for the whole viral replicative capacity under the microen-
vironment.
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Table 1: drug resistant mutation sites of primary variants and variants after culture 4 weeks
first variants fourth variants
Virus variants tropism NRTIs NNRTIs NRTIs NNRTIs
V1 R5X4 - K103N --
V2 R5 - K101*EKQ, Y181C, 
G190A
-G 1 9 0 A
V3 R5X4 T215Y K103N, Y181C T215Y K103N, Y181C
V4 R5X4 D67N, K70R, T215F, K219Q K103N, Y181C D67N, K70R, T215F, K219Q K103N, Y181C
V5 R5X4 L74V Y181C V75T V108I, Y181C
V6 R5X4 - K103N, Y181C - K103N, Y181C
V7 R5X4 M41L, L74V, T215F K101E, Y181C, G190S M41L, L74V, T215F K101E, Y181C, G190S
V8 R5 K65R K103N, Y181C K65R K103N, Y181C
V9 R5 T69APST V108FILV --
V10 R5 M41LM, T215Y K103N, G190A T215Y K103N, G190A
V11 R5X4 A62V, K70KN, V75T Y188L K70N, V75T Y188L
V12 R5X4 - G190EV - G190A
V13 R5 - - - Y181C
-: none; bold: lost after culture; bold and italic: emergent after culture; bold and underline: changed after culture.Publish with BioMed Central    and   every 
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